Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Panacos falls on bevirimat data

PANC fell $1.29 (62%) to $0.80 on Tuesday after data from a Phase IIb trial

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE